CN110123858A - A kind of application of Aplotaxis auriculata essential oil - Google Patents
A kind of application of Aplotaxis auriculata essential oil Download PDFInfo
- Publication number
- CN110123858A CN110123858A CN201910461846.8A CN201910461846A CN110123858A CN 110123858 A CN110123858 A CN 110123858A CN 201910461846 A CN201910461846 A CN 201910461846A CN 110123858 A CN110123858 A CN 110123858A
- Authority
- CN
- China
- Prior art keywords
- essential oil
- aplotaxis auriculata
- mixed liquor
- aplotaxis
- auriculata
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000341 volatile oil Substances 0.000 title claims abstract description 119
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 51
- 238000002360 preparation method Methods 0.000 claims abstract description 31
- 230000003925 brain function Effects 0.000 claims abstract description 26
- 239000003814 drug Substances 0.000 claims abstract description 23
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 22
- 206010039966 Senile dementia Diseases 0.000 claims abstract description 20
- 208000035475 disorder Diseases 0.000 claims abstract description 20
- 229940079593 drug Drugs 0.000 claims abstract description 15
- 208000019901 Anxiety disease Diseases 0.000 claims abstract description 12
- 230000036506 anxiety Effects 0.000 claims abstract description 12
- 238000000605 extraction Methods 0.000 claims description 68
- 239000008187 granular material Substances 0.000 claims description 51
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 48
- 238000000855 fermentation Methods 0.000 claims description 32
- 230000004151 fermentation Effects 0.000 claims description 32
- 239000003921 oil Substances 0.000 claims description 29
- 108010059892 Cellulase Proteins 0.000 claims description 26
- 229940106157 cellulase Drugs 0.000 claims description 26
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 239000000284 extract Substances 0.000 claims description 21
- 238000001256 steam distillation Methods 0.000 claims description 18
- 238000001704 evaporation Methods 0.000 claims description 14
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 13
- 239000007788 liquid Substances 0.000 claims description 13
- 238000000199 molecular distillation Methods 0.000 claims description 13
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 12
- 239000001569 carbon dioxide Substances 0.000 claims description 12
- 230000009977 dual effect Effects 0.000 claims description 12
- 238000010992 reflux Methods 0.000 claims description 12
- NVEQFIOZRFFVFW-RGCMKSIDSA-N caryophyllene oxide Chemical compound C=C1CC[C@H]2O[C@]2(C)CC[C@H]2C(C)(C)C[C@@H]21 NVEQFIOZRFFVFW-RGCMKSIDSA-N 0.000 claims description 10
- 208000020925 Bipolar disease Diseases 0.000 claims description 9
- 244000116484 Inula helenium Species 0.000 claims description 9
- 235000002598 Inula helenium Nutrition 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 9
- 239000002131 composite material Substances 0.000 claims description 8
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 230000004770 neurodegeneration Effects 0.000 claims description 7
- FKWGZOFNSIESOX-QLFBSQMISA-N 2-[(2r,4ar,8as)-4a-methyl-8-methylidene-1,2,3,4,5,6,7,8a-octahydronaphthalen-2-yl]prop-2-en-1-ol Chemical compound C1CCC(=C)[C@@H]2C[C@H](C(=C)CO)CC[C@]21C FKWGZOFNSIESOX-QLFBSQMISA-N 0.000 claims description 6
- JXRNMQDTJAQLAQ-UTZXOHNXSA-N Aplotaxene Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCC=C JXRNMQDTJAQLAQ-UTZXOHNXSA-N 0.000 claims description 6
- ZFSOYHNWYLNZIP-UHFFFAOYSA-N Aplotaxene Natural products CCC=CCC=CC=CCCCCCCC=C ZFSOYHNWYLNZIP-UHFFFAOYSA-N 0.000 claims description 6
- WKSUCCVMYJRMFR-UHFFFAOYSA-N Dehydrocostus lactone Natural products C12OC(=O)C(=C)C2CCC(=C)C2(C)C1(C)C(=C)CC2 WKSUCCVMYJRMFR-UHFFFAOYSA-N 0.000 claims description 6
- JXRNMQDTJAQLAQ-UHFFFAOYSA-N Heptadecatetraen Natural products CCC=CCC=CCC=CCCCCCC=C JXRNMQDTJAQLAQ-UHFFFAOYSA-N 0.000 claims description 6
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 6
- 229930016889 costol Natural products 0.000 claims description 6
- ITRHZWKEZJYJQO-UHFFFAOYSA-N gamma-costol Natural products C1C(C(=C)CO)CCC2(C)CCCC(C)=C21 ITRHZWKEZJYJQO-UHFFFAOYSA-N 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 206010022437 insomnia Diseases 0.000 claims description 6
- 201000000980 schizophrenia Diseases 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- NVEQFIOZRFFVFW-UHFFFAOYSA-N 9-epi-beta-caryophyllene oxide Natural products C=C1CCC2OC2(C)CCC2C(C)(C)CC21 NVEQFIOZRFFVFW-UHFFFAOYSA-N 0.000 claims description 5
- 208000005392 Spasm Diseases 0.000 claims description 5
- RSYBQKUNBFFNDO-UHFFFAOYSA-N caryophyllene oxide Natural products CC1(C)CC2C(=C)CCC3OC3(C)CCC12C RSYBQKUNBFFNDO-UHFFFAOYSA-N 0.000 claims description 5
- 230000007071 enzymatic hydrolysis Effects 0.000 claims description 5
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 claims description 5
- NETSQGRTUNRXEO-UHFFFAOYSA-N 3,6,9-Trimethylidene-3a,4,5,6a,7,8,9a,9b-octahydroazuleno[4,5-b]furan-2-one Chemical compound C12OC(=O)C(=C)C2CCC(=C)C2C1C(=C)CC2 NETSQGRTUNRXEO-UHFFFAOYSA-N 0.000 claims description 4
- 244000251953 Agaricus brunnescens Species 0.000 claims description 4
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims description 4
- 208000023105 Huntington disease Diseases 0.000 claims description 4
- 241000132446 Inula Species 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- YAZBKDRDYPAXAO-UHFFFAOYSA-N dehydro-alpha-curcumene Natural products CC(C)=CCCC(=C)C1=CC=C(C)C=C1 YAZBKDRDYPAXAO-UHFFFAOYSA-N 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 4
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 4
- OZQAPQSEYFAMCY-QLFBSQMISA-N α-selinene Chemical compound C1CC=C(C)[C@@H]2C[C@H](C(=C)C)CC[C@]21C OZQAPQSEYFAMCY-QLFBSQMISA-N 0.000 claims description 4
- 238000004458 analytical method Methods 0.000 claims description 3
- 239000002537 cosmetic Substances 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 238000007920 subcutaneous administration Methods 0.000 claims description 3
- 239000000829 suppository Substances 0.000 claims description 3
- 206010008190 Cerebrovascular accident Diseases 0.000 claims description 2
- 235000007516 Chrysanthemum Nutrition 0.000 claims description 2
- 241000723353 Chrysanthemum Species 0.000 claims description 2
- 241000694034 Dolomiaea Species 0.000 claims description 2
- 241000133134 Saussurea Species 0.000 claims description 2
- 208000020339 Spinal injury Diseases 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- OZQAPQSEYFAMCY-UHFFFAOYSA-N alpha-selinene Natural products C1CC=C(C)C2CC(C(=C)C)CCC21C OZQAPQSEYFAMCY-UHFFFAOYSA-N 0.000 claims description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 2
- 230000003796 beauty Effects 0.000 claims description 2
- 206010015037 epilepsy Diseases 0.000 claims description 2
- 239000003094 microcapsule Substances 0.000 claims description 2
- VPQBJIRQUUEAFC-UHFFFAOYSA-N selinene Natural products C1CC=C(C)C2CC(C(C)C)CCC21C VPQBJIRQUUEAFC-UHFFFAOYSA-N 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims 1
- 239000010931 gold Substances 0.000 claims 1
- 229910052737 gold Inorganic materials 0.000 claims 1
- 230000036541 health Effects 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 16
- 241001465754 Metazoa Species 0.000 abstract description 9
- 208000024891 symptom Diseases 0.000 abstract description 6
- 239000000203 mixture Substances 0.000 abstract description 5
- 102000003914 Cholinesterases Human genes 0.000 abstract description 4
- 108090000322 Cholinesterases Proteins 0.000 abstract description 4
- 229940048961 cholinesterase Drugs 0.000 abstract description 4
- 238000010171 animal model Methods 0.000 abstract description 3
- 230000003001 depressive effect Effects 0.000 abstract description 3
- 230000008499 blood brain barrier function Effects 0.000 abstract description 2
- 210000001218 blood-brain barrier Anatomy 0.000 abstract description 2
- 230000007246 mechanism Effects 0.000 abstract description 2
- 230000002503 metabolic effect Effects 0.000 abstract description 2
- 239000002858 neurotransmitter agent Substances 0.000 abstract description 2
- 230000002110 toxicologic effect Effects 0.000 abstract description 2
- 231100000027 toxicology Toxicity 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 32
- 241000252212 Danio rerio Species 0.000 description 29
- 235000019198 oils Nutrition 0.000 description 27
- 239000002953 phosphate buffered saline Substances 0.000 description 23
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 15
- 229960004424 carbon dioxide Drugs 0.000 description 12
- 238000004821 distillation Methods 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 11
- 239000013641 positive control Substances 0.000 description 11
- 244000272264 Saussurea lappa Species 0.000 description 10
- 235000006784 Saussurea lappa Nutrition 0.000 description 10
- 230000033001 locomotion Effects 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 102100032404 Cholinesterase Human genes 0.000 description 7
- 101710083761 Cholinesterase Proteins 0.000 description 7
- 150000001298 alcohols Chemical class 0.000 description 7
- 229940022698 acetylcholinesterase Drugs 0.000 description 6
- 229910000397 disodium phosphate Inorganic materials 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 239000011550 stock solution Substances 0.000 description 6
- 102100033639 Acetylcholinesterase Human genes 0.000 description 5
- 108010022752 Acetylcholinesterase Proteins 0.000 description 5
- 208000012661 Dyskinesia Diseases 0.000 description 5
- 239000012467 final product Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 241000207955 Inula racemosa Species 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 229960003530 donepezil Drugs 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 229910000162 sodium phosphate Inorganic materials 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 206010010904 Convulsion Diseases 0.000 description 3
- 206010012289 Dementia Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108090000371 Esterases Proteins 0.000 description 3
- ZQPQGKQTIZYFEF-WCVJEAGWSA-N Huperzine Natural products C1([C@H]2[C@H](O)C(=O)N[C@H]2[C@@H](O)C=2C=CC=CC=2)=CC=CC=C1 ZQPQGKQTIZYFEF-WCVJEAGWSA-N 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 238000003287 bathing Methods 0.000 description 3
- 230000036461 convulsion Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000012452 mother liquor Substances 0.000 description 3
- 239000006186 oral dosage form Substances 0.000 description 3
- 238000005453 pelletization Methods 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 229960001685 tacrine Drugs 0.000 description 3
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 3
- 235000020985 whole grains Nutrition 0.000 description 3
- 239000002023 wood Substances 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 2
- 241000448255 Congiopodus peruvianus Species 0.000 description 2
- 241001304297 Dolomiaea berardioidea Species 0.000 description 2
- 241001664472 Dolomiaea calophylla Species 0.000 description 2
- 241000786784 Dolomiaea souliei Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 244000130232 Vangueria edulis Species 0.000 description 2
- 241000107358 Vincetoxicum forrestii Species 0.000 description 2
- RJGPUIBIXSFQED-PBCAYDETSA-N [C@H]1(CC[C@@]2(C)CCC=C(C)[C@@H]2C1)C(C)=C.[C@H]1(CC[C@@]2(C)CCC=C(C)[C@@H]2C1)C(C)=C Chemical compound [C@H]1(CC[C@@]2(C)CCC=C(C)[C@@H]2C1)C(C)=C.[C@H]1(CC[C@@]2(C)CCC=C(C)[C@@H]2C1)C(C)=C RJGPUIBIXSFQED-PBCAYDETSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 239000002249 anxiolytic agent Substances 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000002199 base oil Substances 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 230000019771 cognition Effects 0.000 description 2
- NETSQGRTUNRXEO-XUXIUFHCSA-N dehydrocostus lactone Chemical compound C([C@H]1C(=C)C(=O)O[C@@H]11)CC(=C)[C@H]2[C@@H]1C(=C)CC2 NETSQGRTUNRXEO-XUXIUFHCSA-N 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 239000000686 essence Substances 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 210000001156 gastric mucosa Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000009533 lab test Methods 0.000 description 2
- 238000002386 leaching Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- -1 sorbierite Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 108700024526 zebrafish sox32 Proteins 0.000 description 2
- NTBLZMAMTZXLBP-UHFFFAOYSA-M 2-acetylsulfanylethyl(trimethyl)azanium;iodide Chemical compound [I-].CC(=O)SCC[N+](C)(C)C NTBLZMAMTZXLBP-UHFFFAOYSA-M 0.000 description 1
- SLAMLWHELXOEJZ-UHFFFAOYSA-N 2-nitrobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1[N+]([O-])=O SLAMLWHELXOEJZ-UHFFFAOYSA-N 0.000 description 1
- 208000017194 Affective disease Diseases 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 241000272814 Anser sp. Species 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 206010048650 Cholinesterase inhibition Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283070 Equus zebra Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016777 Flight of ideas Diseases 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- HATRDXDCPOXQJX-UHFFFAOYSA-N Thapsigargin Natural products CCCCCCCC(=O)OC1C(OC(O)C(=C/C)C)C(=C2C3OC(=O)C(C)(O)C3(O)C(CC(C)(OC(=O)C)C12)OC(=O)CCC)C HATRDXDCPOXQJX-UHFFFAOYSA-N 0.000 description 1
- 101001003192 Vigna unguiculata Bowman-Birk type seed trypsin and chymotrypsin inhibitor Proteins 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- HUGQNTGOVJKASF-UHFFFAOYSA-M [SH-].[I+] Chemical compound [SH-].[I+] HUGQNTGOVJKASF-UHFFFAOYSA-M 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 230000000049 anti-anxiety effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 229910002090 carbon oxide Inorganic materials 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000002329 esterase inhibitor Substances 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- KNWQLFOXPQZGPX-UHFFFAOYSA-N methanesulfonyl fluoride Chemical compound CS(F)(=O)=O KNWQLFOXPQZGPX-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000009945 mood elevation Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930009674 sesquiterpene lactone Natural products 0.000 description 1
- 150000002107 sesquiterpene lactone derivatives Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229940072040 tricaine Drugs 0.000 description 1
- FQZJYWMRQDKBQN-UHFFFAOYSA-N tricaine methanesulfonate Chemical compound CS([O-])(=O)=O.CCOC(=O)C1=CC=CC([NH3+])=C1 FQZJYWMRQDKBQN-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 210000001186 vagus nerve Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/285—Aucklandia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L9/00—Disinfection, sterilisation or deodorisation of air
- A61L9/01—Deodorant compositions
- A61L9/013—Deodorant compositions containing animal or plant extracts, or vegetable material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B9/00—Essential oils; Perfumes
- C11B9/02—Recovery or refining of essential oils from raw materials
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B9/00—Essential oils; Perfumes
- C11B9/02—Recovery or refining of essential oils from raw materials
- C11B9/025—Recovery by solvent extraction
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B9/00—Essential oils; Perfumes
- C11B9/02—Recovery or refining of essential oils from raw materials
- C11B9/027—Recovery of volatiles by distillation or stripping
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/10—General cosmetic use
Abstract
The invention discloses a kind of applications of Aplotaxis auriculata essential oil, the application of application, Aplotaxis auriculata essential oil in the health-oriented products that preparation improves brain function and its disorder disease including Aplotaxis auriculata essential oil in the drug that preparation treats or prevents brain function and its disorder disease.Present invention firstly discovers that Aplotaxis auriculata essential oil shows active medicine or big health-oriented products new application in experimental animal brain function and its disorder disease；Find that Aplotaxis auriculata essential oil or essential oil containing Aplotaxis auriculata or its arbitrary composition can improve the symptom of the brain functions such as senile dementia, depressive anxiety and its obstacle animal in model in animal body for the first time.Compared with the drug for the treatment of brain function and its obstacle at present, the Aplotaxis auriculata essential oil or any combination thereof object, which has, to be inhibited cholinesterase, adjusts the mechanism that the polymoleculars such as neurotransmitter act synergistically on multiple target point, and have good medicine for parameter, it is easy to through blood-brain barrier, with toxicological safety, metabolic stability, the characteristics of longer half-life period and/or lesser side effect.
Description
Technical field
The present invention relates to biomedicine technical field, especially a kind of Aplotaxis auriculata essential oil treats and prevents brain function in preparation
And its application in disorder disease drug or health-oriented products.
Background technique
Aplotaxis auriculata is compositae plant radix aucklandiae (Aucklandia lappa Decne.) (Saussurea lappa
Clarke), India is originated in, beam generation is by Guangzhou import.It is mainly cultivated in the ground such as Yunnan, Sichuan, Guangxi at present.Aplotaxis auriculata is done
Dry is Chinese medicine important simply, and history tree is included, and first recorded in Shennong's Herbal, is classified as top grade." China over the years
People's republic's pharmacopeia " also record Aplotaxis auriculata dry root with promoting qi circulation and relieving pain, effect of reinforcing spleen to promote digestion, for treat chest side of body,
Abdominal distention, weight after rush down dysentery, dyspepsia, the diseases such as do not feel like eating.Literature research early period reports that Aplotaxis auriculata contains volatile oil abundant,
Wherein sesquiterpene lactone is the important activity ingredient of Aplotaxis auriculata.Modern pharmacological studies have shown that Aplotaxis auriculata essential oil, which has, adjusts gastrointestinal tract
Movement, protection gastric mucosa, expansion bronchus (inhibit vagus nerve), reduce blood pressure, antibacterial, antitumor, immune system etc. it is a variety of
Pharmacological action.Main mechanism of action be related to accelerate gastrointestinal peristalsis, promote gastric emptying, reduce pungent damage gastric mucosa,
HepG2 cell consumption glucose is influenced, inhibits AKT activity and then induces cell apoptosis, removes free radical, interference tumour cell week
Phase induces cell apoptosis, inhibits platelet aggregation etc..So far, patent there is no to be related to the medical usage of Aplotaxis auriculata essential oil.
Fragrant medicinal plant plays an important role in the treatment or alleviation of brain function and its disorder disease.In the recent period, I
Application cholinesterase activity rating model and compound induce senile dementia zebra fish body in screening model research cloud wood
It when essential oil improves brain function and its disorder disease, finds for the first time, Aplotaxis auriculata essential oil has cholinesterase inhibition, can be significant
Improve the cognition and respond of senile dementia zebra fish.Aplotaxis auriculata essential oil can effectively adjust brain function and its obstacle, can be with
It include brain functions and its disorder diseases such as anxiety, depression, insomnia, neurodegenerative disease for treating/preventing or alleviate.It
Before, this pharmacological action is not yet reported.
Summary of the invention
In view of the above-mentioned deficiencies in the prior art, it is an object of the present invention to provide a kind of application of Aplotaxis auriculata essential oil.
The purpose of the present invention is achieved through the following technical solutions: a kind of application of Aplotaxis auriculata essential oil, the application
It is being made including application of the Aplotaxis auriculata essential oil in the drug that preparation treats or prevents brain function and its disorder disease, Aplotaxis auriculata essential oil
Application in the standby health-oriented products for improving brain function and its disorder disease.
Further, the Aplotaxis auriculata essential oil extracts by the following method obtains:
(1) it ferments: choosing dry Aplotaxis auriculata root, stem, leaf or achene, pile fermentation is placed about 1-2 days, and 30- is then crushed to
The coarse granule of 60 mesh is spare.
(2) it extracts: being extraction in 5.0-6.0 hydrochloric acid or aqueous sulfuric acid by the pH value that coarse granule is soaked in 7-9 times of quality
Overnight, extraction mixed liquor is obtained.
(3) it digests: cellulase and pectase, cellulase, pectase and extraction mixing being added into extraction mixed liquor
The quality proportioning of liquid is 0.5-1:0.1-0.5:100, is digested about 2-3 hours at 35-37 DEG C.
(4) it extracts: the mixed liquor after step 3 enzymatic hydrolysis being put into steam distillation and is extracted in instrument, 100 DEG C of -120 DEG C of reflux
It extracts about 5-7 hour, collection distillate is cooled to room temperature to be placed in oil water separator and separates, oil reservoir anhydrous sodium sulfate
Dry, separation is to get Aplotaxis auriculata essential oil；Or the mixed liquor after step 3 enzymatic hydrolysis is put into CO 2 supercritical and is extracted in instrument,
- 48 DEG C of the temperature 45 C of extraction, pressure 13.70MPa-17.80MPa, time 50min-100min, the flow velocity of carbon dioxide
For 25kg/h-35kg/h；Essential oil is collected, is placed in molecular distillation instrument and refines, feeding temperature is 40 DEG C -45 DEG C, sample introduction speed
For 480-530mL/h, one section of evaporating temperature is 110 DEG C -115 DEG C, and dual circulation temperature is 60 DEG C -65 DEG C, collects two sections of distillations
Part obtains Aplotaxis auriculata essential oil.
Further, the Aplotaxis auriculata is composite family Genus Saussurea plant Aplotaxis auriculata, or is composite family Inulaplants building
Perfume, Tibet inula root, total shape elecampane, or in composite family Dolomiaea plant radix jurineae, vladimiria berardioidesLing, vladimiria edulisLing, vladimiria forrestiiLing, wood
Radix aucklandiae, vladimiria denticulata Ling, or Dendranthema beauty Ye Zangju is hidden for composite family high mountain.
Further, the Aplotaxis auriculata essential oil gas chromatography-mass spectrometry analysis detection, by mass percentage,
Component ratio are as follows: aplotaxene > 20%, costol > 8%, dehydro-α-curcumene > 6%, α-selinene > 5%, carypohyllene oxidation
Object > 4%.
Further, the brain function and its disorder disease include anxiety, depression, insomnia, epilepsy, manic disorder, spirit point
Split disease, spasm, bipolar disorders, apoplexy, Huntington disease, brain trauma, spinal injury and neurodegenerative disease.
Further, the neurodegenerative disease includes senile dementia, Parkinson's disease, Huntington disease and amyotrophic lateral sclerosis side
Rope hardening.
Further, the drug includes oral preparation and non-oral administration preparation；The oral preparation includes tablet, ball
Agent, capsule, granule, microcapsule tablet, suspension, dripping pill, liquid oral；The non-oral administration preparation include inhalant,
Injection, aerosol, suppository, subcutaneous administration dosage form.
Further, the health-oriented products include cosmetics, showering agent and fragrance fumette.
The beneficial effects of the present invention are: the present invention provides a kind of preparation methods of Aplotaxis auriculata essential oil, and cloud is found for the first time
Radix aucklandiae essential oil shows active medicine or big health-oriented products new application in experimental animal brain function and its disorder disease.For the first time
It was found that Aplotaxis auriculata essential oil or essential oil containing Aplotaxis auriculata or its arbitrary composition can improve in model in animal body senile dementia,
The brain functions such as depressive anxiety and its symptom of obstacle animal.Compared with the drug for the treatment of brain function and its obstacle at present, the cloud
Radix aucklandiae essential oil or any combination thereof object, which has, to be inhibited cholinesterase, adjusts the machine that the polymoleculars such as neurotransmitter act synergistically on multiple target point
System, and have good medicine for parameter, it is easy to through blood-brain barrier, having raising/improvement toxicological safety, (i.e. toxicity drops
It is low), raising/improvement metabolic stability, longer half-life period and/or lesser side effect the characteristics of, while generating similar or mentioning
High bioactivity (drug effect).The drug or health-oriented products of preparation can be used for preventing or treating brain function and its disorder disease and disease
Disease, such as anxiety, depression, insomnia, convulsions, manic disorder, schizophrenia, spasm and bipolar disorders.It can also be used in cognitive function
It improves and improves.
Detailed description of the invention
Fig. 1 is the acetylcholine esterase inhibition activity schematic diagram of Aplotaxis auriculata essential oil；
Fig. 2 is the inhibition the activity of BuChE schematic diagram of Aplotaxis auriculata essential oil；
Fig. 3 is the schematic diagram for the respond that Aplotaxis auriculata essential oil restores senile dementia zebra fish；
Fig. 4 is the schematic diagram for the movement speed that Aplotaxis auriculata essential oil restores senile dementia zebra fish.
Specific embodiment
1, it summarizes
Present inventor's discovery, the interior application of animal body Aplotaxis auriculata essential oil of the invention can significantly inhibit cholinesterase,
In compound induction senile dementia zebra fish model, cognition and the reaction energy of senile dementia zebra fish can be significantly improved
Power.In addition, also the depression with anxiety of zebra fish can be can effectively improve in depressive anxiety zebra fish model.That is, cloud
Radix aucklandiae essential oil is coordinated by polymolecular, multiple target effect, the related symptoms for the treatment of/alleviation brain function and its disorder disease, without
It is active that institute can be completely inhibited, toxic side effect also do not occur.
The pathological state of many brain functions and its disorder disease, for example, it is depression and anxiety, convulsions, anxiety, depression, insomnia, mad
Hot-tempered disease, schizophrenia, spasm and bipolar disorders, senile dementia etc., pathogenesis complexity, single component or molecule difficulty and healing
Or alleviate.Aplotaxis auriculata essential oil is made of multiple bioactive molecules, and therefore, the individual with brain function and its disorder disease is acceptable to be contained
There are Aplotaxis auriculata essential oil involved in the present invention, or the composition containing the essential oil containing Aplotaxis auriculata involved in the present invention.
2, exemplary pathological condition
Emotion emotional handicap: the clinical manifestation of emotion emotional handicap is mood elevation or low, with the flight of ideas or late
It is slow, psychomotor excitement or inhibition.This includes from a series of illnesss such as anxiety, depression, schizophrenia, such as mania, division
Affective disorder, schizophrenia, wound bipolar obstacle, panic situation and behavior paroxysmal syndrome out of control etc..According to
Aplotaxis auriculata essential oil of the invention and pharmaceutical formulation and composition can be used for treating these diseases, symptom and the patient's condition, and its with
Existing therapeutic agent in this treatment classification is compared, and should show the improvement to side effect.
Neurodegenerative disease: neurodegenerative disease is to be with dyskinesia caused by the forfeiture of neuron or its myelin
The dyskinesia of feature.Deteriorate over time, to lead to dysfunction, such as Alzheimer's disease etc..The present invention
In Aplotaxis auriculata and its derivative combination alleviate dyskinesia one or more symptoms.
Aplotaxis auriculata essential oil and combinations thereof also is used as anxiolytic (antianxiety) agent in the present invention.
Aplotaxis auriculata essential oil also is used as the chemical tools of brain function and its obstacle study of incident mechanism in the present invention
Brain function and its disorder disease and illness mean the obstacle or disease of nervous system, including but not limited to anxiety, suppression
Strongly fragrant, insomnia, convulsions, manic disorder, schizophrenia, spasm, bipolar disorders and Alzheimer's disease.
Neurodegenerative disease means disease such as, but not limited to below: senile dementia, parkinsonism etc..
Active drug preparation of the invention and composition can be used to treat brain function and its disorder disease and illness.Although this
A little medicine preparations are commonly used in the treatment of human patient, but they can be used for treating the similar or identical disease of other animals
Disease, other described animals such as primate, poultry (such as chicken, duck, goose), farm-animals (such as pig, ox), sports animals
(such as horse racing) and pet (such as dog and cat).
Pharmaceutical acceptable carrier of the present invention includes but is not limited to calcium carbonate, calcium phosphate, calcium sulfate, sucrose, glucose, cream
Sugar, fructose, xylitol, sorbierite, starch, gelatinized corn starch, cellulose derivative, gelatin, polyvinylpyrrolidone, sodium chloride, paste
Essence, stearic acid, magnesium stearate, calcium stearate, vegetable oil, polyethylene glycol, sterile phosphate buffered saline, salt water, woods grignard are molten
Liquid and their combination.
The peroral dosage form of the invention includes but is not limited to that (such as Enteric coated tablets, takes orally dripping pill solid oral dosage form
Piece, chewable tablets, granule, powder or capsule) or liquid oral dosage form (such as syrup or tincture).In addition, the cloud wood in the present invention
Essential oil or combinations thereof object can also be added in cosmetics, bath article or big health-oriented products, for champignon, smell suction, massage,
It smears, bathing uses.In addition, Aplotaxis auriculata essential oil in the present invention or combinations thereof object can also be configured to chewing gum, to promote mouth
Clothes delivering and absorption.
Non-oral dosage forms of the present invention including but not limited to pass through injection or other administered by systemic routes, it is described its
Its systemic pathways such as transdermal administration or mucosal administration (such as intranasal, sublingual, mouth containing, Via vagina or rectum, pass through suppository).
Other administration method (such as can veterinary application used in) include enteral and parenteral delivering, including muscle, it is subcutaneous and/or
Note in intramedullary injection and intrathecal injection, direct intracerebroventricular, intravenous injection, intraperitoneal injection, nasal injection or eyeball
It penetrates.
Aplotaxis auriculata essential oil of the present invention can also be combined with other active components, to prepare other novel drugs combinations
Object.
Confirmation curative effect and treatment related activity of the Aplotaxis auriculata essential oil of the invention or combinations thereof to alleviate above-mentioned symptom,
It is to be confirmed by the test of zebra fish, mouse species senile dementia and depression model and screening technique.
The therapeutic effect of aforementioned present invention Aplotaxis auriculata essential oil or combinations thereof, good drug metabolism parameter and usual nontoxicity
So that the compounds of this invention becomes the ideal medicament for treating above-mentioned illness.
Essentiality content of the invention is further illustrated with the embodiment of the present invention below, but not in any way to this
Invention limits, and is transformed or replaced, is all belonged to the scope of protection of the present invention based on any made by the present invention.
The preparation method of Aplotaxis auriculata essential oil of the present invention, including steam distillation is extracted, CO 2 supercritical mentions
It takes.
Aplotaxis auriculata essential oil of the present invention is detected with gas chromatography-mass spectrometry device, and contained component is by mass percentage
It is calculated as aplotaxene (aplotaxene) (> 20%), costol (costol) (> 8%), dehydro-α-curcumene
(dehydrocostuslactone) (> 6%), α-selinene (α-selinene) (> 5%), caryophyllene oxide
(caryophyllene oxide) (> 4%).
Embodiment 1
The root that takes Aplotaxis auriculata (Aucklandia lappa Decne.) (Saussurea lappa Clarke) dry, stem,
Leaf or achene 100Kg, pile fermentation are placed 2 days, and the coarse granule of 50 mesh is crushed to, and it is 5.0 that coarse granule, which is soaked in 8 mass to measure pH value again,
In aqueous hydrochloric acid solution, extraction is overnight.It is respectively 0.8% cellulase and 0.3% that mass percent, which is added, into extraction mixed liquor
Pectase digests 2.5 hours at 37 DEG C.Above-mentioned sample and its mixed liquor are put into steam distillation to extract in instrument, 110 DEG C are returned
Stream extracts 7 hours, collects distillate, is cooled to room temperature to be placed in oil water separator and separates.Oil reservoir is dry with anhydrous sodium sulfate
Dry, separation is to get Aplotaxis auriculata essential oil.
Embodiment 2
Root, stem, leaf or the achene 120Kg for taking elecampane (Inula helenium L.) dry, pile fermentation are placed 2 days, are crushed
To the coarse granule of 50 mesh, it is in 5.0 aqueous hydrochloric acid solutions that coarse granule, which is soaked in 8 mass to measure pH value again, and extraction is overnight.It is mixed to extraction
Closing and mass percent is added in liquid is respectively 0.8% cellulase and 0.3% pectase, is digested 2.5 hours at 37 DEG C.It will be above-mentioned
Sample and its mixed liquor are put into steam distillation and extract in instrument, and 7 hours of 110 DEG C of refluxing extractions collect distillate, are cooled to
Room temperature is placed in oil water separator and separates.Oil reservoir is dry with anhydrous sodium sulfate, separates to get radix aucklandiae essential oil.
Embodiment 3
Root, stem, leaf or the achene 200Kg for taking Tibet inula root (I.racemosa) dry, pile fermentation are placed 2 days, and pile fermentation places 2
It, is crushed to the coarse granule of 50 mesh, and it is in 5.0 aqueous hydrochloric acid solutions that coarse granule, which is soaked in 8 mass to measure pH value again, and extraction is overnight.
It is respectively 0.8% cellulase and 0.3% pectase that mass percent is added into extraction mixed liquor, and it is small to digest 2.5 at 37 DEG C
When.Above-mentioned sample and its mixed liquor are put into steam distillation to extract in instrument, 7 hours of 110 DEG C of refluxing extractions collect distillation
Liquid, is cooled to room temperature to be placed in oil water separator and separates.Oil reservoir is dry with anhydrous sodium sulfate, separates to get radix aucklandiae essential oil.
Embodiment 4
Root, stem, leaf or the achene 150Kg for taking total shape elecampane (I.racemosa) dry, pile fermentation are placed 2 days, and pile fermentation is put
It sets 2 days, is crushed to the coarse granule of 50 mesh, it is extracted in 5.0 aqueous hydrochloric acid solutions that coarse granule, which is soaked in 8 mass to measure pH value again,
Night.It is respectively 0.8% cellulase and 0.3% pectase that mass percent is added into extraction mixed liquor, digests 2.5 at 37 DEG C
Hour.Above-mentioned sample and its mixed liquor are put into steam distillation to extract in instrument, 7 hours of 110 DEG C of refluxing extractions collect and steam
Distillate, is cooled to room temperature to be placed in oil water separator and separates.Oil reservoir is dry with anhydrous sodium sulfate, separates to get radix aucklandiae essential oil.
Embodiment 5
Root, stem, leaf or the achene 150Kg for taking radix jurineae (V.souliei) dry, pile fermentation are placed 2 days, and 50 purposes are crushed to
Coarse granule, it is in 5.0 aqueous hydrochloric acid solutions that coarse granule, which is soaked in 8 mass to measure pH value again, and extraction is overnight.Add into extraction mixed liquor
Entering mass percent is respectively 0.8% cellulase and 0.3% pectase, is digested 2.5 hours at 37 DEG C.By above-mentioned sample and its
Mixed liquor is put into steam distillation and extracts in instrument, and 7 hours of 110 DEG C of refluxing extractions collect distillate, are cooled to room temperature postposition
It is separated in oil water separator.Oil reservoir is dry with anhydrous sodium sulfate, separates to get radix aucklandiae essential oil.
Embodiment 6
Root, stem, leaf or the achene 150Kg for taking vladimiria berardioidesLing (V.berardioides) dry, pile fermentation are placed 2 days, pile fermentation
It places 2 days, is crushed to the coarse granule of 50 mesh, it is extraction in 5.0 aqueous hydrochloric acid solutions that coarse granule, which is soaked in 8 mass to measure pH value again,
Overnight.It is respectively 0.8% cellulase and 0.3% pectase that mass percent is added into extraction mixed liquor, is digested at 37 DEG C
2.5 hour.Above-mentioned sample and its mixed liquor are put into steam distillation to extract in instrument, 7 hours of 110 DEG C of refluxing extractions receive
Collect distillate, is cooled to room temperature to be placed in oil water separator and separates.Oil reservoir is dry with anhydrous sodium sulfate, separates to get radix aucklandiae
Essential oil.
Embodiment 7
Root, stem, leaf or the achene 150Kg for taking vladimiria edulisLing (V.edulis) dry, pile fermentation are placed 2 days, and pile fermentation is placed 2 days,
It is crushed to the coarse granule of 50 mesh, it is in 5.0 aqueous hydrochloric acid solutions that coarse granule, which is soaked in 8 mass to measure pH value again, and extraction is overnight.To leaching
Mentioning and mass percent is added in mixed liquor is respectively 0.8% cellulase and 0.3% pectase, is digested 2.5 hours at 37 DEG C.It will
Above-mentioned sample and its mixed liquor are put into steam distillation and extract in instrument, 7 hours of 110 DEG C of refluxing extractions, collect distillate, cold
But it is placed in oil water separator and separates to room temperature.Oil reservoir is dry with anhydrous sodium sulfate, separates to get radix aucklandiae essential oil.
Embodiment 8
Root, stem, leaf or the achene 130Kg for taking vladimiria forrestiiLing (V.forrestiis) dry, pile fermentation are placed 2 days, and pile fermentation is put
It sets 2 days, is crushed to the coarse granule of 50 mesh, it is extracted in 5.0 aqueous hydrochloric acid solutions that coarse granule, which is soaked in 8 mass to measure pH value again,
Night.It is respectively 0.8% cellulase and 0.3% pectase that mass percent is added into extraction mixed liquor, digests 2.5 at 37 DEG C
Hour.Above-mentioned sample and its mixed liquor are put into steam distillation to extract in instrument, 7 hours of 110 DEG C of refluxing extractions collect and steam
Distillate, is cooled to room temperature to be placed in oil water separator and separates.Oil reservoir is dry with anhydrous sodium sulfate, separates to get radix aucklandiae essential oil.
Embodiment 9
Root, stem, leaf or the achene 150Kg for taking vladimiria muliensis Ling (V.muliensis.) dry, pile fermentation are placed 2 days, and pile fermentation is put
It sets 2 days, is crushed to the coarse granule of 50 mesh, it is extracted in 5.0 aqueous hydrochloric acid solutions that coarse granule, which is soaked in 8 mass to measure pH value again,
Night.It is respectively 0.8% cellulase and 0.3% pectase that mass percent is added into extraction mixed liquor, digests 2.5 at 37 DEG C
Hour.Above-mentioned sample and its mixed liquor are put into steam distillation to extract in instrument, 7 hours of 110 DEG C of refluxing extractions collect and steam
Distillate, is cooled to room temperature to be placed in oil water separator and separates.Oil reservoir is dry with anhydrous sodium sulfate, separates to get radix aucklandiae essential oil.
Embodiment 10
Root, stem, leaf or the achene 120Kg for taking vladimiria denticulata Ling (V.denticulatai) dry, pile fermentation are placed 2 days, pile fermentation
It places 2 days, is crushed to the coarse granule of 50 mesh, it is extraction in 5.0 aqueous hydrochloric acid solutions that coarse granule, which is soaked in 8 mass to measure pH value again,
Overnight.It is respectively 0.8% cellulase and 0.3% pectase that mass percent is added into extraction mixed liquor, is digested at 37 DEG C
2.5 hour.Above-mentioned sample and its mixed liquor are put into steam distillation to extract in instrument, 7 hours of 110 DEG C of refluxing extractions receive
Collect distillate, is cooled to room temperature to be placed in oil water separator and separates.Oil reservoir is dry with anhydrous sodium sulfate, separates to get radix aucklandiae
Essential oil.
Embodiment 11
Root, stem, leaf or the achene 150Kg for taking beautiful Ye Zangju (Dolomiaea calophylla) dry, pile fermentation place 2
It, pile fermentation is placed 2 days, and the coarse granule of 50 mesh is crushed to, and it is 5.0 aqueous hydrochloric acid solutions that coarse granule, which is soaked in 8 mass to measure pH value again,
In, extraction is overnight.It is respectively 0.8% cellulase and 0.3% pectase that mass percent, which is added, into extraction mixed liquor, 37
DEG C enzymatic hydrolysis 2.5 hours.Above-mentioned sample and its mixed liquor are put into steam distillation to extract in instrument, it is 110 DEG C refluxing extraction 7 small
When, distillate is collected, is cooled to room temperature to be placed in oil water separator and separates.Oil reservoir is dry with anhydrous sodium sulfate, separation to get
Radix aucklandiae essential oil.
Embodiment 12
The root that takes Aplotaxis auriculata (Aucklandia lappa Decne.) (Saussurea lappa Clarke) dry, stem,
Leaf or achene 50Kg, pile fermentation are placed 2 days, and the coarse granule of 50 mesh is crushed to, and it is 5.0 that coarse granule, which is soaked in 8 mass to measure pH value again,
In aqueous hydrochloric acid solution, extraction is overnight.It is respectively 0.8% cellulase and 0.3% that mass percent, which is added, into extraction mixed liquor
Pectase digests 2.5 hours at 37 DEG C.Above-mentioned sample and its mixed liquor are put into CO 2 supercritical to extract in instrument, mentioned
46 DEG C, pressure 15.70MPa, time 85min of the temperature taken, the flow velocity of carbon dioxide is 30kg/h；Essential oil is collected, is placed in
It is refined in molecular distillation instrument, feeding temperature is 43 DEG C, and sample introduction speed is 510mL/h, and one section of evaporating temperature is 112 DEG C, two sections
Evaporating temperature is 63 DEG C, collects two sections of distillation fractions to get radix aucklandiae essential oil.
Embodiment 13
Root, stem, leaf or the achene 70Kg for taking elecampane (Inula helenium L.) dry, pile fermentation are placed 2 days, are crushed
To the coarse granule of 50 mesh, it is in 5.0 aqueous hydrochloric acid solutions that coarse granule, which is soaked in 8 mass to measure pH value again, and extraction is overnight.It is mixed to extraction
Closing and mass percent is added in liquid is respectively 0.8% cellulase and 0.3% pectase, is digested 2.5 hours at 37 DEG C.It will be above-mentioned
Sample and its mixed liquor are put into CO 2 supercritical and extract in instrument, and 46 DEG C, pressure 15.70MPa of the temperature of extraction, the time
For 85min, the flow velocity of carbon dioxide is 30kg/h；Essential oil is collected, is placed in molecular distillation instrument and refines, feeding temperature 43
DEG C, sample introduction speed is 510mL/h, and one section of evaporating temperature is 112 DEG C, and dual circulation temperature is 63 DEG C, two sections of distillation fractions are collected,
Up to radix aucklandiae essential oil.
Embodiment 14
Root, stem, leaf or the achene 30Kg for taking Tibet inula root (I.racemosa) dry, pile fermentation are placed 2 days, and 50 purposes are crushed to
Coarse granule, it is in 5.0 aqueous hydrochloric acid solutions that coarse granule, which is soaked in 8 mass to measure pH value again, and extraction is overnight.Add into extraction mixed liquor
Entering mass percent is respectively 0.8% cellulase and 0.3% pectase, is digested 2.5 hours at 37 DEG C.By above-mentioned sample and its
Mixed liquor is put into CO 2 supercritical and extracts in instrument, and 46 DEG C, pressure 15.70MPa, time 85min of the temperature of extraction,
The flow velocity of carbon dioxide is 30kg/h；Essential oil is collected, is placed in molecular distillation instrument and refines, feeding temperature is 43 DEG C, sample introduction speed
Degree is 510mL/h, and one section of evaporating temperature is 112 DEG C, and dual circulation temperature is 63 DEG C, collects two sections of distillation fractions to get radix aucklandiae
Essential oil.
Embodiment 15
Root, stem, leaf or the achene 80Kg for taking total shape elecampane (I.racemosa) dry, pile fermentation are placed 2 days, are crushed to 50
Purpose coarse granule, it is in 5.0 aqueous hydrochloric acid solutions that coarse granule, which is soaked in 8 mass to measure pH value again, and extraction is overnight.To extraction mixed liquor
Middle addition mass percent is respectively 0.8% cellulase and 0.3% pectase, is digested 2.5 hours at 37 DEG C.By above-mentioned sample
And its mixed liquor is put into CO 2 supercritical and extracts in instrument, 46 DEG C, pressure 15.70MPa of the temperature of extraction, the time is
85min, the flow velocity of carbon dioxide are 30kg/h；Essential oil to be collected, is placed in molecular distillation instrument and refines, feeding temperature is 43 DEG C,
Sample introduction speed is 510mL/h, and one section of evaporating temperature is 112 DEG C, and dual circulation temperature is 63 DEG C, collects two sections of distillation fractions, i.e.,
Obtain radix aucklandiae essential oil.
Embodiment 16
Root, stem, leaf or the achene 50Kg for taking radix jurineae (V.souliei) dry, pile fermentation are placed 2 days, and 50 purposes are crushed to
Coarse granule, it is in 5.0 aqueous hydrochloric acid solutions that coarse granule, which is soaked in 8 mass to measure pH value again, and extraction is overnight.Add into extraction mixed liquor
Entering mass percent is respectively 0.8% cellulase and 0.3% pectase, is digested 2.5 hours at 37 DEG C.By above-mentioned sample and its
Mixed liquor is put into CO 2 supercritical and extracts in instrument, and 46 DEG C, pressure 15.70MPa, time 85min of the temperature of extraction,
The flow velocity of carbon dioxide is 30kg/h；Essential oil is collected, is placed in molecular distillation instrument and refines, feeding temperature is 43 DEG C, sample introduction speed
Degree is 510mL/h, and one section of evaporating temperature is 112 DEG C, and dual circulation temperature is 63 DEG C, collects two sections of distillation fractions to get radix aucklandiae
Essential oil.
Embodiment 17
Root, stem, leaf or the achene 50Kg for taking vladimiria berardioidesLing (V.berardioides) dry, pile fermentation are placed 2 days, are crushed to
The coarse granule of 50 mesh, it is in 5.0 aqueous hydrochloric acid solutions that coarse granule, which is soaked in 8 mass to measure pH value again, and extraction is overnight.It is mixed to extraction
It is respectively 0.8% cellulase and 0.3% pectase that mass percent is added in liquid, is digested 2.5 hours at 37 DEG C.By above-mentioned sample
Product and its mixed liquor are put into CO 2 supercritical and extract in instrument, and 46 DEG C, pressure 15.70MPa of the temperature of extraction, the time is
85min, the flow velocity of carbon dioxide are 30kg/h；Essential oil to be collected, is placed in molecular distillation instrument and refines, feeding temperature is 43 DEG C,
Sample introduction speed is 510mL/h, and one section of evaporating temperature is 112 DEG C, and dual circulation temperature is 63 DEG C, collects two sections of distillation fractions, i.e.,
Obtain radix aucklandiae essential oil.
Embodiment 18
Root, stem, leaf or the achene 50Kg for taking vladimiria edulisLing (V.edulis) dry, pile fermentation are placed 2 days, and it is thick to be crushed to 50 purposes
Particle, it is in 5.0 aqueous hydrochloric acid solutions that coarse granule, which is soaked in 8 mass to measure pH value again, and extraction is overnight.It is added into extraction mixed liquor
Mass percent is respectively 0.8% cellulase and 0.3% pectase, is digested 2.5 hours at 37 DEG C.By above-mentioned sample and its mix
It closes liquid to be put into CO 2 supercritical extraction instrument, 46 DEG C, pressure 15.70MPa, time 85min of the temperature of extraction, two
The flow velocity of carbonoxide is 30kg/h；Essential oil is collected, is placed in molecular distillation instrument and refines, feeding temperature is 43 DEG C, sample introduction speed
For 510mL/h, one section of evaporating temperature is 112 DEG C, and dual circulation temperature is 63 DEG C, collects two sections of distillation fractions to get radix aucklandiae essence
Oil.
Embodiment 19
Root, stem, leaf or the achene 45Kg for taking vladimiria forrestiiLing (V.forrestiis) dry, pile fermentation are placed 2 days, are crushed to 50
Purpose coarse granule, it is in 5.0 aqueous hydrochloric acid solutions that coarse granule, which is soaked in 8 mass to measure pH value again, and extraction is overnight.To extraction mixed liquor
Middle addition mass percent is respectively 0.8% cellulase and 0.3% pectase, is digested 2.5 hours at 37 DEG C.By above-mentioned sample
And its mixed liquor is put into CO 2 supercritical and extracts in instrument, 46 DEG C, pressure 15.70MPa of the temperature of extraction, the time is
85min, the flow velocity of carbon dioxide are 30kg/h；Essential oil to be collected, is placed in molecular distillation instrument and refines, feeding temperature is 43 DEG C,
Sample introduction speed is 510mL/h, and one section of evaporating temperature is 112 DEG C, and dual circulation temperature is 63 DEG C, collects two sections of distillation fractions, i.e.,
Obtain radix aucklandiae essential oil.
Embodiment 20
Root, stem, leaf or the achene 50Kg for taking vladimiria muliensis Ling (V.muliensis.) dry, pile fermentation are placed 2 days, are crushed to 50
Purpose coarse granule, it is in 5.0 aqueous hydrochloric acid solutions that coarse granule, which is soaked in 8 mass to measure pH value again, and extraction is overnight.To extraction mixed liquor
Middle addition mass percent is respectively 0.8% cellulase and 0.3% pectase, is digested 2.5 hours at 37 DEG C.By above-mentioned sample
And its mixed liquor is put into CO 2 supercritical and extracts in instrument, 46 DEG C, pressure 15.70MPa of the temperature of extraction, the time is
85min, the flow velocity of carbon dioxide are 30kg/h；Essential oil to be collected, is placed in molecular distillation instrument and refines, feeding temperature is 43 DEG C,
Sample introduction speed is 510mL/h, and one section of evaporating temperature is 112 DEG C, and dual circulation temperature is 63 DEG C, collects two sections of distillation fractions, i.e.,
Obtain radix aucklandiae essential oil.
Embodiment 21
Root, stem, leaf or the achene 40Kg for taking vladimiria denticulata Ling (V.denticulatai) dry, pile fermentation are placed 2 days, are crushed to
The coarse granule of 50 mesh, it is in 5.0 aqueous hydrochloric acid solutions that coarse granule, which is soaked in 8 mass to measure pH value again, and extraction is overnight.It is mixed to extraction
It is respectively 0.8% cellulase and 0.3% pectase that mass percent is added in liquid, is digested 2.5 hours at 37 DEG C.By above-mentioned sample
Product and its mixed liquor are put into CO 2 supercritical and extract in instrument, and 46 DEG C, pressure 15.70MPa of the temperature of extraction, the time is
85min, the flow velocity of carbon dioxide are 30kg/h；Essential oil to be collected, is placed in molecular distillation instrument and refines, feeding temperature is 43 DEG C,
Sample introduction speed is 510mL/h, and one section of evaporating temperature is 112 DEG C, and dual circulation temperature is 63 DEG C, collects two sections of distillation fractions, i.e.,
Obtain radix aucklandiae essential oil.
Embodiment 22
Root, stem, leaf or the achene 50Kg for taking beautiful Ye Zangju (Dolomiaea calophylla) dry, pile fermentation are placed 2 days,
It is crushed to the coarse granule of 50 mesh, it is in 5.0 aqueous hydrochloric acid solutions that coarse granule, which is soaked in 8 mass to measure pH value again, and extraction is overnight.To leaching
Mentioning and mass percent is added in mixed liquor is respectively 0.8% cellulase and 0.3% pectase, is digested 2.5 hours at 37 DEG C.It will
Above-mentioned sample and its mixed liquor are put into CO 2 supercritical and extract in instrument, and 46 DEG C, pressure 15.70MPa of the temperature of extraction,
Time is 85min, and the flow velocity of carbon dioxide is 30kg/h；Essential oil is collected, is placed in molecular distillation instrument and refines, feeding temperature is
43 DEG C, sample introduction speed is 510mL/h, and one section of evaporating temperature is 112 DEG C, and dual circulation temperature is 63 DEG C, collects two sections of distillers
Divide to get radix aucklandiae essential oil.
Embodiment 23
GC-MS analysis is carried out with the Aplotaxis auriculata essential oil that embodiment 1-22 is prepared.Contained component is by mass percentage
For aplotaxene (aplotaxene) (> 20%), costol (costol) (> 8%), dehydro-α-curcumene
(dehydrocostuslactone) (> 6%), α-selinene (α-selinene) (> 5%), caryophyllene oxide
(caryophyllene oxide) (> 4%).
Embodiment 24
Anti-acetylcholinesterase activity test is carried out with the Aplotaxis auriculata essential oil that embodiment 1 is prepared:
Take NaH2PO4·2H2O 3.121g is dissolved in water, and is dissolved to 100mL and obtains the NaH of 0.2moL/L2PO4；
Na2HPO4·12H2O 71.64g is dissolved in water, and is dissolved to 1000mL and obtains the Na of 0.2mol/L2HPO4.Take above-mentioned preparation
26.5mL NaH2PO4With 473.5mL Na2HPO4After being sufficiently mixed, the PBS of 0.2moL/L pH=8.0 is obtained, then by this solution
1 times of dilution obtains the PBS of 0.1moL/L pH=8.0；B. the 39mL NaH of above-mentioned preparation is taken2PO4With 61mL Na2HPO4Sufficiently
After mixing, the PBS of 0.2moL/L pH=7.0 is obtained, then this solution is diluted 1 times, obtain 0.1moL/L pH=7.0PBS.
It is first configured to the mother liquor of 1000U/mL acetylcholinesterase (AchE) with the PBS of pH=8.0, then is diluted to 4U/mL
- 80 DEG C of stock solution preservations, stock solution is diluted to the acetylcholine ester enzyme solution of 0.4U/mL by when experiment again.Accurately weigh 8.8mg
ATCI (acetylthiocholine iodide), is dissolved in deionized water, is dissolved to 50mL, 4 DEG C of placements (ready-to-use)；0.6mmoL/L
The preparation of DTNB [bis- thiobis of 5,5'- (2- nitrobenzoic acid)]: 11.9mg DTNB and 0.75g NaHCO are accurately weighed3It is dissolved in
In the PBS of pH=7.0, it is dissolved to 50mL, (ready-to-use) is kept in dark place.Positive drug huperzine is made into hplc grade methanol
The initial concentration of 10mg/mL, determinand are made into the initial concentration of 100mg/mL with hplc grade methanol.When experiment positive control and to
It surveys object and is diluted to 5 concentration (positive controls: 100,10,1,0.1,0.01mg/mL；Determinand: 100,50,25,12.5,
6.25mg/mL), each concentration does 3 groups of parallel laboratory tests.It is respectively divided into following several groups of tests: experimental group: 40 μ L PBS (pH=
8.0), 10 μ L determinand, the AchE solution of 10 μ L 0.4U/mL, 20 μ L 0.6mmoL/L DTNB are sequentially added in 96 orifice plates, and 37
DEG C 10min is incubated in advance, then again plus 20 μ L 0.6mmoL/L ATCI are in 37 DEG C of isothermal reaction 30min, then again plus the 50 anhydrous second of μ L
Alcohol terminates reaction.Experiment control group: 40 μ L PBS (pH=8.0), 10 μ L determinands, 10 μ L PBS (pH=8.0), 20 μ L
0.6mmoL/L DTNB is sequentially added in 96 orifice plates, and 37 DEG C incubate 10min in advance, then adds 20 μ L 0.6mmoL/L ATCI in 37 again
DEG C isothermal reaction 30min, then again plus 50 μ L dehydrated alcohols terminate reaction.Blank group: 40 μ L PBS (pH=8.0), 10 μ L first
Alcohol, the AchE solution of 10 μ L 0.4U/mL, 20 μ L 0.6mmoL/L DTNB are sequentially added in 96 orifice plates, and 37 DEG C incubate 10min in advance,
Then add 20 μ L 0.6mmoL/L ATCI in 37 DEG C of isothermal reaction 30min again, then add 50 μ L dehydrated alcohols to terminate reaction again.
Blank control group: 40 μ L PBS (pH=8.0), 10 μ L methanol, PBS (pH=8.0), 20 μ L 0.6mmoL/L DTNB successively add
Enter in 96 orifice plates, 37 DEG C incubate 10min in advance, then add 20 μ L 0.6mmoL/L ATCI in 37 DEG C of isothermal reaction 30min again, then
Again plus 50 μ L dehydrated alcohols terminate reaction.
With microplate reader, Detection wavelength, calculating inhibiting rate formula are as follows at 412nm:
The result shows that the Aplotaxis auriculata essential oil of (table 1 and Fig. 1) all tests is shown under 1mg/mL concentration inhibits acetyl gallbladder
The effect of alkali esterase, it is suitable with positive control huperzine.
Table 1: inhibiting activity of acetylcholinesterase test
| Compound name | IC50(mg/mL) |
| Aplotaxis auriculata (Aucklandia lappa Decne.) rhizome steam distillation essential oil | 0.0169±0.0058 |
| Positive controls (huperzine) | 0.0032±0.0001 |
Embodiment 25
Anti-butyrylcholinesterase active testing is carried out with the Aplotaxis auriculata essential oil that embodiment 1 is prepared:
Take NaH2PO4·2H2O 3.121g is dissolved in water, and is dissolved to 100mL and obtains the NaH of 0.2moL/L2PO4；
Na2HPO4·12H2O 71.64g is dissolved in water, and is dissolved to 1000mL and obtains the Na of 0.2mol/L2HPO4.Take above-mentioned preparation
26.5mL NaH2PO4With 473.5mL Na2HPO4After being sufficiently mixed, the PBS of 0.2moL/L pH=8.0 is obtained, then by this solution
1 times of dilution obtains the PBS of 0.1moL/L pH=8.0；B. the 39mL NaH of above-mentioned preparation is taken2PO4With 61mL Na2HPO4Sufficiently
After mixing, the PBS of 0.2moL/L pH=7.0 is obtained, then this solution is diluted 1 times, obtain 0.1moL/L pH=7.0PBS.
It is first configured to the mother liquor of 1000U/mL butyrylcholine esterase (BchE) with the PBS of pH=8.0, then is diluted to 4U/mL
- 80 DEG C of stock solution preservations, stock solution is diluted to the butyrylcholine esterase liquid of 0.4U/mL by when experiment again.Accurately weigh 2.5mg
BTCI (iodine bisulfide is for BuCh), is dissolved in deionized water, is dissolved to 50mL, 4 DEG C of placements (ready-to-use)；By BuCh
Esterase (BChE) powder is sufficiently dissolved with the PBS of pH=8.0, is configured to 500U/mL mother liquor, then is diluted to 8U/ml stock solution -80
It DEG C saves, stock solution is diluted to the butyrylcholine esterase liquid of 0.8U/mL by when experiment again；DTNB configuration method is same as above.Positive drug
Tacrine is made into 10 μM of initial concentration with hplc grade methanol, and when experiment dilutes 5 gradients, and each concentration does 3 groups of parallel laboratory tests.
It is respectively divided into following several groups of tests: experimental group: 40 μ L PBS (pH=8.0), 10 μ L determinands, the BchE of 10 μ L 0.4U/mL
Solution, 20 μ L 0.6mmoL/L DTNB are sequentially added in 96 orifice plates, and 37 DEG C incubate 10min in advance, then add 20 μ L 0.6mmoL/L again
Then ATCI adds 50 μ L dehydrated alcohols to terminate reaction again in 37 DEG C of isothermal reaction 30min.Experiment control group: 40 μ L PBS (pH=
8.0), 10 μ L determinand, 10 μ L PBS (pH=8.0), 20 μ L 0.6mmoL/L DTNB are sequentially added in 96 orifice plates, and 37 DEG C pre-
10min is incubated, then adds 20 μ L 0.6mmoL/L ATCI in 37 DEG C of isothermal reaction 30min again, then adds 50 μ L dehydrated alcohols whole again
Only react.Blank group: 40 μ L PBS (pH=8.0), 10 μ L methanol, the BchE solution of 10 μ L 0.4U/mL, 20 μ L 0.6mmoL/
L DTNB is sequentially added in 96 orifice plates, and 37 DEG C incubate 10min in advance, then adds 20 μ L 0.6mmoL/L ATCI anti-in 37 DEG C of constant temperature again
30min is answered, then adds 50 μ L dehydrated alcohols to terminate reaction again.Blank control group: 40 μ L PBS (pH=8.0), 10 μ L methanol,
PBS (pH=8.0), 20 μ L 0.6mmoL/L DTNB are sequentially added in 96 orifice plates, and 37 DEG C incubate 10min in advance, then add 20 μ L again
Then 0.6mmoL/L ATCI adds 50 μ L dehydrated alcohols to terminate reaction again in 37 DEG C of isothermal reaction 30min.
With microplate reader, Detection wavelength, calculating inhibiting rate formula are as follows at 412nm:
The result shows that the Aplotaxis auriculata essential oil of (table 2 and Fig. 2) all tests is shown under 1mg/mL concentration inhibits butyryl gallbladder
The effect of alkali esterase, it is suitable with positive control Tacrine.
Table 2: butyrylcholine esterase inhibitory activity test
| Compound name | IC50(mg/mL) |
| Aplotaxis auriculata (Aucklandia lappa Decne.) rhizome steam distillation essential oil | 0.0216±0.0060 |
| Positive controls (Tacrine) | 0.0194±0.0030 |
Embodiment 26
Internal anti-senile dementia disease active testing is carried out with the Aplotaxis auriculata essential oil that embodiment 1 is prepared:
1) experimental animal
The zebra fish juvenile fish of experiment produces embryo by zebra fingerling fish and is incubated for naturally.Fish culture water water quality: every 1L
200mg Instant Ocean is added in reverse osmosis water, conductivity is 480~510 μ S/cm；PH is 6.9~7.2；Hardness be 53.7~
71.6mg/L CaCO3.After the completion of experiment, carried out with zebra fish of the tricaine methanesulfonic acid of 0.25mg/ml to each stage of development
Anesthesia is put to death.The operating procedure that anesthesia is put to death meets the code requirement that American Veterinary association (AVMA) puts to death Animal Anesthesia.
2) experimental design
5 groups of experiments are arranged in this research altogether, and every group of experiment is silly including 1 blank control group, 1 solvent control group, 1 old age
Slow-witted model group, 1 positive controls (donepezil), 22 Aplotaxis auriculata essential oils.The primary dcreening operation concentration of Aplotaxis auriculata essential oil is 6 μ g/mL,
If there is dead or deformity, 0.6 μ g/mL is chosen, is tested.The zebra fish of alchlor processing is Senlie dementia model
Group；The zebra fish that alchlor and DPZ are jointly processed by is positive controls；The spot that alchlor and untested compound are jointly processed by
Horse fish is untested compound group；The zebra fish of 0.1% DMSO processing is negative control group (solvent control group)；Untreated spot
Horse fish is blank control group, and each experimental group handles 30 tail zebra fish.Utilize zebra fish in behavioural analysis instrument record 60min
Motion profile is changed by light dark period, dark 10min, and 10min, 60min points of illumination are three light dark periods, then right
The movement velocity (dyskinesia) of zebra fish, light and shade period velocity variation (respond) carry out statistical analysis.
Active testing result meets quality control standard: 1. all experimental groups do not occur zebra fish in whole experiment process
Dead or deformity；2. model group and solvent control group compare with statistical difference (p < 0.001)；3. blank pair in all experiments
According to group compared with solvent control group no difference of science of statistics (p > 0.05)；4. positive controls (donepezil, DPZ) and model group ratio
Relatively there is statistical difference (p < 0.05).
3) to the restitution of senile dementia zebra fish dyskinesia
All experiment Senlie dementia model group zebra fish movement velocitys are remarkably decreased, and have statistics compared with solvent control group
It learns meaning (p < 0.001)；Positive drug (DPZ) group zebra fish movement velocity is significantly gone up, and is anticipated compared with model group with statistics
Adopted (p < 0.01 or p < 0.001).For zebra fish within the 60min light and shade period, movement velocity has regularity, periodicity and stabilization
Property.The movement velocity of the Aplotaxis auriculata essential oil being prepared with embodiment 1 treated AD zebra fish significantly mentions compared with model group
High (p < 0.05, p < 0.01 or p < 0.001), the significant movement velocity (table 3 and Fig. 3) for restoring senile dementia zebra fish.
Table 3: the therapeutic efficiency of senile dementia zebra fish movement velocity
| Compound name | Concentration (μ g/mL) | Therapeutic efficiency % | P value |
| Aplotaxis auriculata (Aucklandia lappa Decne.) rhizome steam distillation essential oil | 6.00 | 86.68 | 5.94E-07 |
| Positive controls (donepezil) | 3.79 | 68.95 | 5.11E-07 |
4) to the influence of senile dementia zebra fish respond
In all experiments, Senlie dementia model group zebra fish respond declines (under light and shade period velocity difference is significant
Drop), it is statistically significant compared with solvent control group (p < 0.001)；It is extensive that positive drug (DPZ) organizes zebra fish respond part
Multiple (light and shade period velocity difference is significantly gone up), with statistical significance (p < 0.05 or p < 0.001) compared with model group.With reality
Apply after the Aplotaxis auriculata essential oil processing that example 1 is prepared can recovery AD zebra fish in various degree respond (the light and shade period
Speed difference significantly gos up), compared with model group, statistical difference is significant or extremely significant (p < 0.05, p < 0.01 or p < 0.001)
(table 4 and Fig. 4).
Table 4: the therapeutic efficiency of senile dementia zebra fish respond
| Compound name | Concentration (μ g/mL) | Therapeutic efficiency % | P value |
| Aplotaxis auriculata (Aucklandia lappa Decne.) rhizome steam distillation essential oil | 6.00 | 91.27 | 2.63E-07 |
| Positive controls (donepezil) | 3.79 | 73.84 | 9.55E-11 |
Embodiment 27
The Aplotaxis auriculata essential oil progress active testing being prepared respectively with embodiment 2-22, test method and embodiment 24,
25 embodiment 26 of embodiment is identical, and the Aplotaxis auriculata essential oil for as a result showing that the present invention is prepared can significantly improve alchlor
Induce the locomitivity and respond of senile dementia zebra fish.
Embodiment 28: the preparation of Aplotaxis auriculata essential oil tablet
Aplotaxis auriculata essential oil 10mL, medical starch 100g are uniformly mixed, and ethanol in proper amount is used to pelletize as adhesive, dry, warp
Pelletizing machine whole grain, tabletting, every 0.30g take orally, and 1 to 2 tablets once, twice daily.
Embodiment 29: the preparation of Aplotaxis auriculata essential oil capsules agent
Aplotaxis auriculata essential oil 10mL, medical starch 100g are uniformly mixed, and ethanol in proper amount is used to pelletize as adhesive, dry, warp
Pelletizing machine whole grain, encapsulated, every 0.30g take orally, 1-2 tablets each time, twice daily.
Embodiment 30: the preparation of Aplotaxis auriculata essential oil granules agent
Aplotaxis auriculata essential oil 10mL, medical starch 100g, Icing Sugar 500g are uniformly mixed, use ethanol in proper amount as adhesive system
Grain, it is dry, through pelletizing machine whole grain, dispenses to obtain the final product, take orally, each 5g, twice daily
Embodiment 31: the preparation of Aplotaxis auriculata essential oil sucking preparation
Aplotaxis auriculata essential oil 10mL, base oil 500mL, appropriate stabilizer and deodorant tune are uniformly mixed, and are dispensed to obtain the final product, sucking,
Each 10mL, twice daily.
Embodiment 32: the preparation of Aplotaxis auriculata essential oil massage oil
Aplotaxis auriculata essential oil 10mL, base oil 500mL are uniformly mixed, and are dispensed to obtain the final product, and massage is 2-3 times daily.
Embodiment 33: the preparation of Aplotaxis auriculata essential oil bathing agent
Aplotaxis auriculata essential oil 100mL, dispenses to obtain the final product, when bathing, instills in water and uses, and 2-3 times weekly.
Embodiment 34: the preparation of Aplotaxis auriculata essential oil champignon oil
Aplotaxis auriculata essential oil 100mL, dispenses to obtain the final product, when champignon, instills in fumigating machine and uses, 2-3 times daily.
Above-described embodiment is used to illustrate the present invention, rather than limits the invention, in spirit of the invention and
In scope of protection of the claims, to any modifications and changes that the present invention makes, protection scope of the present invention is both fallen within.
Claims (8)
1. a kind of application of Aplotaxis auriculata essential oil, which is characterized in that the application includes that Aplotaxis auriculata essential oil is treated or prevented in preparation
Application, Aplotaxis auriculata essential oil in the drug of brain function and its disorder disease improve the health of brain function and its disorder disease in preparation
Application in product.
2. application according to claim 1, which is characterized in that the Aplotaxis auriculata essential oil extracts by the following method to be obtained:
(1) it ferments: choosing dry Aplotaxis auriculata root, stem, leaf or achene, pile fermentation is placed about 1-2 days, and 30-60 mesh is then crushed to
Coarse granule it is spare.
(2) it extracts: being extracted in 5.0-6.0 hydrochloric acid or aqueous sulfuric acid by the pH value that coarse granule is soaked in 7-9 times of quality
Night obtains extraction mixed liquor.
(3) it digests: being added cellulase and pectase into extraction mixed liquor, cellulase, pectase and extraction mixed liquor
Quality proportioning is 0.5-1:0.1-0.5:100, is digested about 2-3 hours at 35-37 DEG C.
(4) it extracts: the mixed liquor after step 3 enzymatic hydrolysis being put into steam distillation and is extracted in instrument, 100 DEG C of -120 DEG C of refluxing extractions
About 5-7 hour collects distillate, is cooled to room temperature to be placed in oil water separator and separates, oil reservoir is dry with anhydrous sodium sulfate,
Separation is to get Aplotaxis auriculata essential oil；Or the mixed liquor after step 3 enzymatic hydrolysis is put into CO 2 supercritical and is extracted in instrument, it extracts
- 48 DEG C of temperature 45 C, the flow velocity of pressure 13.70MPa-17.80MPa, time 50min-100min, carbon dioxide is
25kg/h-35kg/h；Essential oil is collected, is placed in molecular distillation instrument and refines, feeding temperature is 40 DEG C -45 DEG C, and sample introduction speed is
480-530mL/h, one section of evaporating temperature are 110 DEG C -115 DEG C, and dual circulation temperature is 60 DEG C -65 DEG C, collect two sections of distillers
Point, obtain Aplotaxis auriculata essential oil.
3. application according to claim 1, which is characterized in that the Aplotaxis auriculata is composite family Genus Saussurea plant Aplotaxis auriculata,
It or is composite family Inulaplants elecampane, Tibet inula root, total shape elecampane, or be composite family Dolomiaea plant radix jurineae, thick leaf
Radix aucklandiae, vladimiria edulisLing, vladimiria forrestiiLing, vladimiria muliensis Ling, vladimiria denticulata Ling, or Dendranthema beauty Ye Zangju is hidden for composite family high mountain.
4. application according to claim 1, which is characterized in that Aplotaxis auriculata essential oil gas chromatography-mass spectrometry point
Analysis detection, by mass percentage, component ratio are as follows: aplotaxene > 20%, costol > 8%, dehydro-α-curcumene > 6%,
α-selinene > 5%, caryophyllene oxide > 4%.
5. application according to claim 1, which is characterized in that the brain function and its disorder disease include anxiety, depression,
Insomnia, epilepsy, manic disorder, schizophrenia, spasm, bipolar disorders, apoplexy, Huntington disease, brain trauma, spinal injury and nerve
Degenerative disease.
6. application according to claim 5, which is characterized in that the neurodegenerative disease includes senile dementia, pa gold
Gloomy disease, Huntington disease and amyotrophic lateral sclerosis.
7. application according to claim 1, which is characterized in that the drug includes oral preparation and non-oral administration system
Agent；The oral preparation includes tablet, pill, capsule, granule, microcapsule tablet, suspension, dripping pill, liquid oral；It is described
Non-oral administration preparation includes inhalant, injection, aerosol, suppository, subcutaneous administration dosage form.
8. application according to claim 1, which is characterized in that the health-oriented products include cosmetics, showering agent and champignon
Agent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910461846.8A CN110123858A (en) | 2019-05-30 | 2019-05-30 | A kind of application of Aplotaxis auriculata essential oil |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910461846.8A CN110123858A (en) | 2019-05-30 | 2019-05-30 | A kind of application of Aplotaxis auriculata essential oil |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110123858A true CN110123858A (en) | 2019-08-16 |
Family
ID=67582855
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910461846.8A Withdrawn CN110123858A (en) | 2019-05-30 | 2019-05-30 | A kind of application of Aplotaxis auriculata essential oil |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110123858A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111481603A (en) * | 2020-04-29 | 2020-08-04 | 广东轻工职业技术学院 | Essential oil composition with α -glycosidase inhibitory activity and blood sugar reducing function and preparation method and application thereof |
| CN111529515A (en) * | 2020-06-08 | 2020-08-14 | 中国科学院昆明植物研究所 | Application of 12, 15-dioxo-alpha-cnidiene in pharmacy |
-
2019
- 2019-05-30 CN CN201910461846.8A patent/CN110123858A/en not_active Withdrawn
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111481603A (en) * | 2020-04-29 | 2020-08-04 | 广东轻工职业技术学院 | Essential oil composition with α -glycosidase inhibitory activity and blood sugar reducing function and preparation method and application thereof |
| CN111529515A (en) * | 2020-06-08 | 2020-08-14 | 中国科学院昆明植物研究所 | Application of 12, 15-dioxo-alpha-cnidiene in pharmacy |
| WO2021249236A1 (en) * | 2020-06-08 | 2021-12-16 | 中国科学院昆明植物研究所 | USE OF 12,15-DIOXO-α-SELENENE IN PHARMACEUTICALS |
| CN111529515B (en) * | 2020-06-08 | 2022-06-21 | 中国科学院昆明植物研究所 | Application of 12, 15-dioxo-alpha-cnidiene in pharmacy |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110151823A (en) | A kind of application of cinnamon essential oil | |
| CN106963820A (en) | The purposes of Piper plants essential oil | |
| CN1927383B (en) | Compound recipe preparation for lowering oxidative stress rapidly and preparation method therefor | |
| CN104922176B (en) | A kind of application of Flos Chrysanthemi Indici extract | |
| CN106420886A (en) | Composition with physical fatigue alleviating and immunity enhancing functions, and preparation method thereof | |
| CN110123858A (en) | A kind of application of Aplotaxis auriculata essential oil | |
| CN110123989A (en) | A kind of application of curcuma zedoary essential oil | |
| CN110384725A (en) | A kind of preparation of Chinese traditional medicine composition and its activity extract for adjusting oral cavity flora | |
| TWI662965B (en) | A composition comprising cistanche and ginkgo extracts, the composition useful for improving memory of a subject | |
| CN101474383B (en) | Preparation method of garlic total saponin as well as products produced thereby and application | |
| CN105663204A (en) | Composition and preparation capable of improving immune function, resisting fatigue and treating cold as well as preparation method and application of composition | |
| CN110123982A (en) | A kind of application of tsaoko essential oil | |
| KR101999742B1 (en) | Composition comprising ethanol extract of Aster scaber for preventon or treatment of neuropathic pain | |
| CN110279748A (en) | A kind of application of Cortex Magnoliae Officinalis essential oil | |
| CN110123848A (en) | A kind of application of deodar essential oil | |
| CN110279734A (en) | A kind of application of angelica essential oil | |
| CN114699424B (en) | New application of bacteroides fragilis zwitterionic capsular polysaccharide and/or modified zwitterionic capsular polysaccharide | |
| CN110151809A (en) | A kind of application of Rhizoma Atractylodis Macrocephalae essential oil | |
| CN110251634A (en) | A kind of application of Amomum cardamomum essential oil | |
| KR101509056B1 (en) | Composition having brain function and congnition enhancing activity comprising ginseng mixed herbal extracts, ginsenoside Rg2 and ginsenoside F2 | |
| CN110201013A (en) | A kind of application of radix saposhnikoviae essential oil | |
| WO2014038878A2 (en) | Composition for brain-neuron protection and brain-disease prevention, alleviation or treatment comprising muskrat musk | |
| KR20040026277A (en) | The health-supporting food being effective the sexual energy strength and its preparat ion method | |
| CN110448582A (en) | A kind of application of Rhizoma Chuanxiong essential oil | |
| CN105166896B (en) | A kind of health food of auxiliary improvement of memory power |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20190816 |
|
| WW01 | Invention patent application withdrawn after publication |